A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

被引：0
|
作者：
Yoon, Sang Eun [1 ]
Jung, Sung-Hoon [2 ]
Lee, Gyeong Won [3 ]
Min, Chang-Ki [4 ]
Byun, Ja Min [5 ]
Kwak, Jae-Yong [6 ]
Lee, Myung-Won [7 ]
Lee, Ho Sup [8 ]
Kim, Seok Jin [9 ]
Kim, Kihyun [1 ,10 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Samsung Med Ctr,Dept Med, Seoul, South Korea
[2] Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, Hwasun, South Korea
[3] Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp, Dept Internal Med, Jinju, South Korea
[4] Catholic Univ Korea, Catholic Hematol Hosp, Seoul St Marys Hosp, Dept Hematol,Coll Med, Seoul, South Korea
[5] Seoul Natl Univ, Seoul, South Korea
[6] Chonbuk Natl Univ, Med Sch, Jeonju, South Korea
[7] Chungnam Natl Univ, Coll Med, Dept Internal Med, Daejeon, South Korea
[8] Kosin Univ Gospel Hosp, Dept Internal Med, Busan, South Korea
[9] Samsung Med Ctr, Seoul, South Korea
[10] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198947
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7045 / 7046
页数：2
相关论文
共 50 条
  • [31] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Kazuhito Suzuki
    Nobuhiro Tsukada
    Noriko Nishimura
    Yasuyuki Nagata
    Kiyoshi Okazuka
    Yuko Mishima
    Masahiro Yokoyama
    Kaichi Nishiwaki
    Tadao Ishida
    Shingo Yano
    Yasuhito Terui
    Kenshi Suzuki
    International Journal of Hematology, 2020, 111 : 103 - 111
  • [32] Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
    Hulin, Cyrille
    Offner, Fritz
    Moreau, Philippe
    Roussel, Murielle
    Belhadj, Karim
    Benboubker, Lotfi
    Caillot, Denis
    Facon, Thierry
    Garderet, Laurent
    Kuhnowski, Frederique
    Stoppa, Anne-Marie
    Kolb, Brigitte
    Tiab, Mourad
    Jie, Kon-Siong
    Westerman, Matthijs
    Lambert, Jerome
    Pei, Lixia
    Vanquickelberghe, Veronique
    de Boer, Carla
    Vermeulen, Jessica
    Kampfenkel, Tobias
    Sonneveld, Pieter
    van de Donk, Niels W. C. J.
    HAEMATOLOGICA, 2021, 106 (08) : 2257 - 2260
  • [33] Real-World Data on the Daratumumab Plus Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
    Crusoe, Edvan de Queiroz
    Ribeiro, Glaciano
    Moura, Fernanda
    Costa, Abel
    Aranha, Milton
    Bittencourt, Rosane
    Ribeiro, Eduardo
    Neto, Jorge
    Cunha, Rafael
    Mattos, Ederson
    Braga, Walter
    Lima, Juliana Souza
    Gusmao, Breno
    Lopes, Danielle Ovigli
    Berg, Luiza
    Souto, Joao
    Maiolino, Angelo
    Hungria, Vania T. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S223 - S223
  • [34] BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VERSUS BORTEZOMIB-CYCLOPHOSPHAMIDE- DEXAMETHASONE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
    Al-Hashmi, H.
    LEUKEMIA RESEARCH, 2017, 61 : S55 - S55
  • [35] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
    Joseph, Nisha
    Kaufman, Jonathan
    Lonial, Sagar
    Hofmeister, Craig
    Dhodapkar, Madhav
    Gupta, Vikas
    DiCamillo, Sara
    Roberts, Danielle
    Boise, Lawrence
    Nooka, Ajay
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113
  • [36] Bortezomib-lenalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation: A single center experience
    Kaloyannidis, P.
    Abduljalil, O.
    Abdulbaqi, M.
    Jatham, A.
    Estanislao, A.
    Raslan, H.
    Moinuddin, A.
    Apostolidis, J.
    Al Sagheir, A.
    Al Hashmi, H.
    Al Anazi, K.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S462 - S462
  • [37] A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
    O'Donnell, Elizabeth
    Laubach, Jacob P.
    Yee, Andrew J.
    Huff, Carol Ann
    Basile, Frank
    Wade, Philip M.
    Paba-Prada, Claudia E.
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Couture, Nicole
    Doherty, Lauren
    Lyons, Hannah
    English, Caroline
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur
    BLOOD, 2014, 124 (21)
  • [38] Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients
    Korde, Neha
    Zingone, Adriana
    Kwok, Mary
    Manasanch, Elisabet E.
    Costello, Rene
    Zuchlinski, Diamond
    Mulquin, Marcia
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul C.
    Yuan, Constance
    Tembhare, Prashant Ramesh
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Raffeld, Mark
    Xi, Liqiang
    Choyke, Peter
    Kurdziel, Karen
    Lindenberg, Liza
    Steinberg, Seth M.
    Roschewski, Mark
    Landgren, Ola
    BLOOD, 2012, 120 (21)
  • [39] EFFICACY AND SAFETY OF WEEKLY INFUSION BORTEZOMIB IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Bringhen, S.
    Genuardi, M.
    Rossi, D.
    Petrucci, M.
    Andriani, A.
    Rizzi, R.
    Mele, G.
    Aitoro, G.
    Mettivier, V.
    Annibali, O.
    Rossini, F.
    Gentilini, P.
    Pavone, V.
    Cellini, C.
    Giuliani, N.
    Rauco, A.
    Baraldi, A.
    Dominietto, A.
    Capaldi, A.
    Pescosta, N.
    Rizzi, R.
    Nozza, A.
    Spadano, A.
    De Stefano, V.
    Holanek, M.
    Gaidano, G.
    Boccadoro, M.
    Palumbo, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 149 - 149
  • [40] Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
    Ocio, Enrique M.
    Perrot, Aurore
    Bories, Pierre
    San-Miguel, Jesus F.
    Blau, Igor W.
    Karlin, Lionel
    Martinez-Lopez, Joaquin
    Wang, Song-Yau
    Bringhen, Sara
    Marcatti, Magda
    Mateos, Maria-Victoria
    Rodriguez-Otero, Paula
    Oliva, Stefania
    Nogai, Axel
    Le Roux, Nadia
    Dong, Liyan
    Mace, Sandrine
    Gassiot, Matthieu
    Fitzmaurice, Thomas
    Oprea, Corina
    Moreau, Philippe
    LEUKEMIA, 2023, 37 (07) : 1521 - 1529
12345